CCDC106

Across TCGA pan-cancer cohorts, CCDC106 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCDC106 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCDC106 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC106 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

LUAD, GBM, and LSCC are the cancer types where CCDC106 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.362	0.697	.018	8	view →
GBM	OS	Tertile	All	0.971	0.701	.019	4	view →
LSCC	OS	Tertile	All	1.000	0.732	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCDC106–LUAD (DFS)

Open the LUAD breakdown →